RACE ONCOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.275 AUD | -2.67% |
|
0.00% | +51.79% |
| Mar. 26 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
| Mar. 18 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15.9 | 4.358 | 81.52 | 527.2 | 311.1 | 199.8 |
| Enterprise Value (EV) 1 | 12.19 | 3.37 | 79.78 | 517.9 | 277.5 | 178.2 |
| P/E ratio | -2.23 x | -1.15 x | -19.4 x | -75.8 x | -26.7 x | -19.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 93.4 x | 19.1 x | 511 x | 1,361 x | 439 x | 63.7 x |
| EV / Revenue | 71.6 x | 14.7 x | 501 x | 1,337 x | 392 x | 56.9 x |
| EV / EBITDA | -2.01 x | -0.99 x | -21.9 x | -85.2 x | -25.4 x | -17.5 x |
| EV / FCF | -7.88 x | -2.55 x | -63.3 x | -242 x | -132 x | -24.2 x |
| FCF Yield | -12.7% | -39.2% | -1.58% | -0.41% | -0.76% | -4.13% |
| Price to Book | 2.01 x | 0.86 x | 14.3 x | 38.4 x | 8.61 x | 7.84 x |
| Nbr of stocks (in thousands) | 75,736 | 82,236 | 116,450 | 143,651 | 159,520 | 163,069 |
| Reference price 2 | 0.2100 | 0.0530 | 0.7000 | 3.670 | 1.950 | 1.225 |
| Announcement Date | 8/21/18 | 8/23/19 | 8/27/20 | 8/26/21 | 8/26/22 | 8/30/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.1703 | 0.2285 | 0.1594 | 0.3874 | 0.7078 | 3.134 |
| EBITDA 1 | -6.071 | -3.389 | -3.649 | -6.078 | -10.92 | -10.19 |
| EBIT 1 | -6.322 | -3.671 | -3.931 | -6.359 | -11.2 | -10.48 |
| Operating Margin | -3,713.01% | -1,606.35% | -2,466.26% | -1,641.48% | -1,582.76% | -334.22% |
| Earnings before Tax (EBT) 1 | -6.306 | -3.659 | -3.846 | -6.34 | -11.2 | -9.923 |
| Net income 1 | -6.306 | -3.659 | -3.846 | -6.34 | -11.2 | -9.923 |
| Net margin | -3,703.97% | -1,601.48% | -2,413.22% | -1,636.7% | -1,582.63% | -316.6% |
| EPS 2 | -0.0940 | -0.0460 | -0.0361 | -0.0484 | -0.0731 | -0.0617 |
| Free Cash Flow 1 | -1.548 | -1.323 | -1.261 | -2.139 | -2.097 | -7.356 |
| FCF margin | -909.02% | -578.79% | -791.44% | -552.13% | -296.2% | -234.69% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/21/18 | 8/23/19 | 8/27/20 | 8/26/21 | 8/26/22 | 8/30/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.71 | 0.99 | 1.73 | 9.32 | 33.5 | 21.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.55 | -1.32 | -1.26 | -2.14 | -2.1 | -7.36 |
| ROE (net income / shareholders' equity) | -93% | -56.4% | -71.6% | -65.3% | -45% | -32.2% |
| ROA (Net income/ Total Assets) | -55.5% | -34% | -44% | -39.4% | -27% | -20.4% |
| Assets 1 | 11.37 | 10.75 | 8.748 | 16.1 | 41.41 | 48.62 |
| Book Value Per Share 2 | 0.1000 | 0.0600 | 0.0500 | 0.1000 | 0.2300 | 0.1600 |
| Cash Flow per Share 2 | 0.0500 | 0.0100 | 0.0100 | 0.0600 | 0.2100 | 0.1300 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 8/21/18 | 8/23/19 | 8/27/20 | 8/26/21 | 8/26/22 | 8/30/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +51.79% | 142M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RAC Stock
- Financials Race Oncology Limited
